TY - JOUR
T1 - Tackling the Patient with Multiple Drug “Allergies”
T2 - Multiple Drug Intolerance Syndrome
AU - Guyer, Autumn
AU - Iammatteo, Melissa
AU - Karagic, Merhunisa
AU - Macy, Eric
AU - Jerschow, Elina
N1 - Funding Information:
Conflicts of interest: A. Guyer reports personal fees from Bayer Corp. for expert testimony and personal fees from UpToDate royalties, outside the submitted work. E. Jerschow reports personal fees from Sanofi/Regeneron, GlaxoSmithKline, and Novartis/Genentech; and reports a research grant from Cumberland Pharmaceuticals , outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.
Publisher Copyright:
© 2020
PY - 2020/10
Y1 - 2020/10
N2 - As populations age, the prevalence of reported drug “allergy” increases, often leading to suboptimal care and increased morbidity because of unnecessary avoidance of safe and effective medications. Evaluation by a drug allergy specialist is often warranted when a patient has more than 2 unrelated drug “allergies” listed in the medical record. In this commentary, we clarify and propose standard terminology to use when evaluating patients with multiple drug allergy labels including and more specifically when diagnosing multiple drug intolerance syndrome and the much rarer multiple drug hypersensitivity syndrome. We review epidemiology and key features of multiple drug intolerance syndrome and multiple drug hypersensitivity syndrome. We summarize the methodologic and practical diagnostic workup and management of individuals with MDIS to assist with the accurate delabeling of drug “allergies” in the electronic health record.
AB - As populations age, the prevalence of reported drug “allergy” increases, often leading to suboptimal care and increased morbidity because of unnecessary avoidance of safe and effective medications. Evaluation by a drug allergy specialist is often warranted when a patient has more than 2 unrelated drug “allergies” listed in the medical record. In this commentary, we clarify and propose standard terminology to use when evaluating patients with multiple drug allergy labels including and more specifically when diagnosing multiple drug intolerance syndrome and the much rarer multiple drug hypersensitivity syndrome. We review epidemiology and key features of multiple drug intolerance syndrome and multiple drug hypersensitivity syndrome. We summarize the methodologic and practical diagnostic workup and management of individuals with MDIS to assist with the accurate delabeling of drug “allergies” in the electronic health record.
KW - Drug allergy
KW - Drug challenge
KW - Drug hypersensitivity
KW - Drug intolerance
KW - Multiple drug hypersensitivity syndrome
KW - Multiple drug intolerance syndrome
UR - http://www.scopus.com/inward/record.url?scp=85091735268&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091735268&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2020.08.033
DO - 10.1016/j.jaip.2020.08.033
M3 - Article
C2 - 33039011
AN - SCOPUS:85091735268
SN - 2213-2198
VL - 8
SP - 2870
EP - 2876
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 9
ER -